Retinopathy of Prematurity

Retinopathy of Prematurity

Introduction to Retinopathy of Prematurity (ROP)

Retinopathy of Prematurity (ROP) is a potentially blinding eye disorder that primarily affects premature infants. It is characterized by abnormal blood vessel development in the retina of premature infants.

Key Points:

  • Incidence increases with decreasing gestational age and birth weight.
  • Major cause of childhood blindness worldwide, especially in middle-income countries.
  • Timely screening and intervention can significantly reduce the risk of severe visual impairment.
  • Understanding of pathophysiology has led to improved screening protocols and treatment modalities.

Historical Context:

First described in the 1940s, ROP was initially known as retrolental fibroplasia. Its association with excessive oxygen therapy led to restricted oxygen use in the 1950s, reducing ROP incidence but increasing mortality. Modern neonatal care aims to balance oxygen needs with ROP risk.

Pathophysiology of ROP

Normal Retinal Vascularization:

  • Begins at 16 weeks of gestation from the optic disc.
  • Proceeds anteriorly, reaching the ora serrata nasally at 36 weeks and temporally at 40 weeks.

Pathological Process in ROP:

  1. Phase I (Vasoobliteration):
    • Hyperoxia leads to downregulation of VEGF and IGF-1.
    • Results in cessation of normal vessel growth and regression of existing vessels.
  2. Phase II (Vasoproliferation):
    • Relative hypoxia in the avascular retina triggers upregulation of angiogenic factors (VEGF, EPO).
    • Leads to abnormal neovascularization at the junction of vascularized and avascular retina.

Key Factors in ROP Development:

  • Prematurity: Immature retinal vasculature is more susceptible to injury.
  • Oxygen exposure: Fluctuations in oxygen levels are particularly damaging.
  • Low birth weight: Correlated with increased ROP risk.
  • Genetic factors: Some evidence for genetic predisposition.
  • Comorbidities: Sepsis, IVH, and other neonatal complications may increase risk.

Classification and Staging of ROP

The International Classification of Retinopathy of Prematurity (ICROP) is used to describe the location and severity of ROP.

Location:

  • Zone I: Circle with radius twice the distance from the optic disc to the macula.
  • Zone II: Extends from the edge of zone I to the nasal ora serrata.
  • Zone III: Remaining temporal crescent of retina.

Staging:

  1. Stage 1: Demarcation line between vascular and avascular retina.
  2. Stage 2: Ridge - the demarcation line has height and width.
  3. Stage 3: Ridge with extraretinal fibrovascular proliferation.
  4. Stage 4: Partial retinal detachment.
    • 4A: Extrafoveal
    • 4B: Including fovea
  5. Stage 5: Total retinal detachment.

Additional Descriptors:

  • Plus Disease: Increased venous dilatation and arteriolar tortuosity of posterior pole vessels.
  • Pre-plus Disease: Vascular abnormalities insufficient for plus disease diagnosis but more than normal.
  • Aggressive Posterior ROP (AP-ROP): Severe form with rapid progression, typically in zone I or posterior zone II.

Screening and Diagnosis of ROP

Screening Guidelines:

Vary by country, but generally include:

  • All infants with birth weight ≤1500 g or gestational age ≤30 weeks.
  • Selected infants with birth weight 1500-2000 g or gestational age >30 weeks with unstable clinical course.

Timing of Initial Screening:

  • No later than 31 weeks postmenstrual age or 4 weeks chronological age, whichever is later.
  • Earlier screening may be indicated for extremely premature infants or those with stormy neonatal course.

Screening Procedure:

  1. Pupillary dilation with tropicamide 0.5% and phenylephrine 2.5%.
  2. Indirect ophthalmoscopy with scleral depression.
  3. Use of wide-field digital imaging systems (e.g., RetCam) is increasing, especially for telemedicine applications.

Follow-up Schedule:

  • Depends on findings at initial and subsequent examinations.
  • Can range from 1 week to 3 weeks based on zone and stage of ROP.
  • Continues until full vascularization or regression of ROP.

Differential Diagnosis:

  • Persistent fetal vasculature
  • Familial exudative vitreoretinopathy
  • Incontinentia pigmenti
  • Norrie disease

Management and Treatment of ROP

Prevention:

  • Careful oxygen management: Target SpO2 90-95% for premature infants.
  • Optimal nutrition: Ensure adequate protein and calorie intake.
  • Prevention of comorbidities: Manage sepsis, anemia, and other risk factors.

Treatment Indications:

Based on the ETROP study, treatment is indicated for:

  • Type 1 ROP:
    • Zone I, any stage with plus disease
    • Zone I, stage 3 without plus disease
    • Zone II, stage 2 or 3 with plus disease

Treatment Modalities:

  1. Laser Photocoagulation:
    • Gold standard treatment.
    • Ablation of avascular retina to reduce VEGF production.
    • Usually performed under general anesthesia.
  2. Anti-VEGF Therapy:
    • Intravitreal injection of bevacizumab or ranibizumab.
    • Particularly useful for zone I disease or aggressive posterior ROP.
    • Concerns about systemic absorption and long-term effects.
  3. Surgical Management:
    • Vitrectomy or scleral buckling for stages 4 and 5.
    • Limited success in advanced stages.

Post-treatment Follow-up:

  • Weekly examinations until regression of neovascularization.
  • Monitor for recurrence, especially with anti-VEGF treatment.
  • Long-term follow-up for refractive errors, amblyopia, and strabismus.

Prognosis and Follow-up

Visual Outcomes:

  • Highly variable, depending on severity and treatment timing.
  • Mild ROP (stages 1-2): Generally good prognosis with spontaneous regression.
  • Severe ROP (stages 3-5): Higher risk of unfavorable visual outcomes.
  • Treated ROP: 80-90% favorable structural outcomes with timely intervention.

Associated Ocular Complications:

  • Myopia: Common, especially in treated eyes.
  • Strabismus: Occurs in up to 30% of ROP patients.
  • Amblyopia: May result from uncorrected refractive errors or strabismus.
  • Glaucoma: Late complication, especially in advanced stages.
  • Retinal detachment: Risk persists into adulthood.

Long-term Follow-up:

  1. Frequent eye examinations in first year of life.
  2. Annual comprehensive eye exams throughout childhood and adolescence.
  3. Refractive error correction and amblyopia treatment as needed.
  4. Monitoring for late complications (e.g., retinal tears, glaucoma).

Neurodevelopmental Outcomes:

  • Increased risk of cognitive and motor delays, especially in severe ROP.
  • Multidisciplinary follow-up recommended (ophthalmology, neurology, developmental pediatrics).

Future Directions:

  • Ongoing research into biomarkers for ROP prediction and progression.
  • Development of less invasive treatment modalities.
  • Improvements in imaging technology for more accurate diagnosis and monitoring.
  • Potential for stem cell therapy in advanced stages.


Retinopathy of Prematurity
  1. What is the primary risk factor for developing retinopathy of prematurity (ROP)?
    Extreme prematurity (gestational age less than 28 weeks)
  2. Which part of the retina is primarily affected in ROP?
    The peripheral retina
  3. What is the role of oxygen therapy in the pathogenesis of ROP?
    Excessive oxygen can lead to abnormal retinal vascularization
  4. What is the international classification system used for staging ROP?
    The International Classification of Retinopathy of Prematurity (ICROP)
  5. At what postmenstrual age should screening for ROP typically begin?
    31 weeks or 4 weeks after birth, whichever is later
  6. What is the "gold standard" method for diagnosing ROP?
    Indirect ophthalmoscopy by an experienced ophthalmologist
  7. Which zone of the retina, when affected by ROP, indicates the most severe disease?
    Zone I (posterior pole)
  8. What does "plus disease" refer to in ROP?
    Dilation and tortuosity of retinal blood vessels
  9. What is the primary goal of treatment for ROP?
    To prevent retinal detachment and preserve vision
  10. Which treatment modality has largely replaced cryotherapy for ROP?
    Laser photocoagulation
  11. What is the role of anti-VEGF therapy in treating ROP?
    Used for severe cases, particularly zone I disease
  12. What long-term visual complication is associated with severe ROP?
    Myopia
  13. How does birth weight correlate with the risk of developing ROP?
    Inversely correlated; lower birth weight increases risk
  14. What is the typical age of onset for ROP in extremely preterm infants?
    30-32 weeks postmenstrual age
  15. What is the significance of "threshold disease" in ROP?
    Indicates the need for immediate treatment to prevent progression
  16. How does the incidence of ROP differ between developed and developing countries?
    Higher in developing countries due to less controlled oxygen therapy and neonatal care
  17. What is the role of genetic factors in the development of ROP?
    May influence susceptibility and disease severity
  18. How does race affect the risk of developing severe ROP?
    African American infants have a lower risk compared to Caucasian infants
  19. What is the recommended follow-up schedule for infants with regressing ROP?
    Every 1-2 weeks until full vascularization of the retina
  20. What is the role of telemedicine in ROP screening?
    Can improve access to screening in remote areas through remote image interpretation
  21. How does maternal preeclampsia affect the risk of ROP in preterm infants?
    May have a protective effect, possibly due to in-utero stress
  22. What is the significance of "aggressive posterior ROP" (AP-ROP)?
    Rapidly progressive form of ROP with poor prognosis if untreated
  23. How does bronchopulmonary dysplasia (BPD) relate to the development of ROP?
    BPD is associated with an increased risk of developing ROP
  24. What is the role of insulin-like growth factor 1 (IGF-1) in the pathogenesis of ROP?
    Low levels of IGF-1 in preterm infants may contribute to abnormal retinal vascularization
  25. How does multiple gestation affect the risk of ROP?
    Multiple births are associated with an increased risk of ROP
  26. What is the recommended timing for treatment once threshold ROP is diagnosed?
    Within 72 hours
  27. How does the use of antenatal corticosteroids affect the risk of ROP?
    May reduce the risk of severe ROP
  28. What is the role of erythropoietin in the development of ROP?
    High levels may increase the risk of ROP progression
  29. How does sepsis in preterm infants affect the risk of developing ROP?
    Increases the risk of ROP, possibly due to inflammatory processes
  30. What is the significance of "skip areas" in ROP?
    Untreated areas of avascular retina that may lead to late reactivation of ROP


Further Reading
Tags:

Powered by Blogger.